藥 物 回 收
|
| |
| Canada: Recall: CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE: The level of the degradation product Benzaldehyde is out of specification in the affected lots (English only) |
| |
Health Canada announces that Omega Laboratories Ltd. is recalling 2 lots of Cisatracurium Besylate Injection USP Multidose (cisatracurium besilate 2mg/ml) (lot number: B3L78VA, B3M79VA) from retailers because the level of the degradation product Benzaldehyde is out of specification in the affected lots.
The product is non-depolarizing skeletal neuromuscular blocking agent with an intermediate onset and duration of action indicated as an adjunct to general anesthesia, to facilitate non-emergency endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Please refer to the following website in Health Canada for details:
http://recalls-rappels.canada.ca/en/alert-recall/cisatracurium-besylate-injection-usp-multidose-level-degradation-product-benzaldehyde
In Hong Kong, the above product is not a registered pharmaceutical product.
Ends/Wednesday, Feb 19, 2025
Issued at HKT 15:30
|
| |
